← Drug-vs-drug verdicts

Mounjaro vs Saxenda (2026): Weekly T2D Dual-Agonist vs Daily Obesity GLP-1

Mounjaro (tirzepatide, Eli Lilly) vs Saxenda (liraglutide, Novo Nordisk)

Last verified 2026-05-28

By Eli Marsden · Founding Editor
Editorially reviewed (not clinically reviewed) · How we verify contentLast reviewed

The verdict

Mounjaro (tirzepatide) and Saxenda (liraglutide) are not real competitors — they treat different conditions on different schedules. Mounjaro is a once-weekly dual GIP/GLP-1 agonist FDA-approved for type 2 diabetes, with A1C reductions ~2.3% and weight loss of 7-12 kg at higher doses. Saxenda is a once-daily GLP-1 mono-agonist FDA-approved for chronic weight management, producing ~8% weight loss in SCALE Obesity. Saxenda also has pediatric approval (ages 12+). If you want weight loss and have T2D, the right comparison is usually Mounjaro vs Wegovy or Zepbound, not Saxenda.

Side-by-side comparison

FieldMounjaroSaxenda
FDA-approved indicationType 2 diabetes mellitus (adults)Chronic weight management (adults BMI ≥30 or ≥27 + comorbidity; pediatric 12+ ≥60 kg)
ManufacturerEli LillyNovo Nordisk
MechanismDual GIP / GLP-1 receptor agonistGLP-1 receptor agonist (mono)
Dosing frequencyOnce-weekly subcutaneous injectionOnce-daily subcutaneous injection
Half-life~5 days (tirzepatide)~13 hours (liraglutide)
Weight loss (pivotal trial)−7-12% body weight in SURPASS T2D trials; −20.9% / 72 wk in SURMOUNT-1 (as Zepbound)−8.0% / 56 wk in SCALE Obesity (Pi-Sunyer 2015)
Cardiovascular outcome trialSURPASS-CVOT pending 2027LEADER: MACE −13% (HR 0.87) at liraglutide 1.8 mg in T2D + high CV risk
Cash price (US, ~2026)~$1,069/mo WAC; LillyDirect savings card for commercially insured T2D patients~$1,349/mo retail; no manufacturer cash-pay program comparable to Wegovy/Zepbound
Pediatric approvalNot approved in pediatricsApproved ages 12+ with body weight ≥60 kg and BMI corresponding to adult ≥30

Frequently asked questions

Are Mounjaro and Saxenda competing drugs?

Not really. They treat different FDA-labeled conditions on different schedules. Mounjaro (tirzepatide, Eli Lilly) is a once-weekly injection approved for type 2 diabetes. Saxenda (liraglutide, Novo Nordisk) is a once-daily injection approved for chronic weight management. They are different molecules from different manufacturers with different mechanisms (dual GIP/GLP-1 vs GLP-1 mono). Patients hearing about both at the same time often assume they are alternatives, but most clinicians choose between Mounjaro and a weight-loss drug like Wegovy or Zepbound, or between Saxenda and Wegovy — not across this gap.

Should I switch from Saxenda to Mounjaro to lose more weight?

If your goal is weight loss alone, the more apples-to-apples switch is from Saxenda to Zepbound, which is tirzepatide labeled for obesity. Mounjaro itself is labeled only for type 2 diabetes, so most insurance plans will not authorize it for weight loss without a T2D diagnosis. SURMOUNT-1 (Jastreboff 2022 NEJM, PMID 35658024) showed tirzepatide produced −20.9% body weight at 72 weeks vs Saxenda's −8% over 56 weeks in SCALE Obesity (Pi-Sunyer 2015 NEJM, PMID 26132939) — a substantially larger effect. Discuss the switch with a prescriber who can submit the appropriate prior authorization.

Can I take Mounjaro and Saxenda together?

No. Both drugs act on the GLP-1 receptor (Mounjaro additionally acts on the GIP receptor), and combining two GLP-1-active agents is not supported by any FDA label or clinical guideline. The combination would substantially increase the risk of gastrointestinal adverse events, pancreatitis, and hypoglycemia if used with insulin or sulfonylureas, without evidence of added benefit. Clinicians switch between these drugs but do not stack them.

Why does my doctor prescribe Mounjaro instead of Saxenda?

Most often because the indication matches a type 2 diabetes diagnosis. Mounjaro carries an A1C-lowering label that triggers commercial insurance coverage for T2D patients; Saxenda is labeled only for chronic weight management, which many employer plans exclude. Mounjaro is also once-weekly versus Saxenda's daily injection, which improves adherence. Finally, SURPASS-2 (Frías 2021 NEJM, PMID 34170647) and other head-to-head data show tirzepatide produces larger A1C and weight reductions than liraglutide-class drugs at comparable doses.

Why is Saxenda still on the market when newer drugs exist?

Three reasons. First, Saxenda is the only GLP-1 weight-management drug FDA-approved for adolescents aged 12 and older (with body weight at least 60 kg) — Wegovy added a pediatric indication later, but Saxenda retains a long pediatric track record. Second, LEADER (Marso 2016 NEJM, PMID 27295427) gives liraglutide an established cardiovascular-outcome dataset (−13% MACE at the T2D 1.8 mg dose; the 3.0 mg Saxenda dose extrapolates that safety profile). Third, daily liraglutide cycles out of the body in about 13 hours — useful when a clinician wants the option to stop the drug quickly before surgery, pregnancy planning, or severe GI intolerance, compared to tirzepatide's ~5-day half-life that lingers for weeks.

What is the cash price difference?

Both drugs are expensive at U.S. retail. Mounjaro lists around $1,069/month wholesale; Eli Lilly offers a savings card that can reduce the copay to as low as $25/month for commercially insured patients with type 2 diabetes, but cash payers and Medicare/Medicaid patients are excluded. Saxenda retails around $1,349/month and does not have a manufacturer cash-pay program comparable to Wegovy's NovoCare $349-$499 tier. For weight-loss patients without insurance coverage, neither drug is a practical cash-pay choice — Zepbound at $349-$499 via LillyDirect or Wegovy at $349-$499 via NovoCare are typically lower-cost options.

References

  1. 1.Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). N Engl J Med. 2015. PMID: 26132939.
  2. 2.Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021. PMID: 34170647.
  3. 3.Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. 2016. PMID: 27295427.
  4. 4.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024.
  5. 5.Eli Lilly and Company. MOUNJARO (tirzepatide) injection — FDA prescribing information. DailyMed (NIH/NLM). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  6. 6.Novo Nordisk. SAXENDA (liraglutide) injection — FDA prescribing information. DailyMed (NIH/NLM). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
  7. 7.Eli Lilly and Company. Mounjaro savings card eligibility — commercially insured patients with type 2 diabetes. LillyDirect. 2026. https://www.lillydirect.lilly.com/pharmacy/mounjaro

Related comparisons

See the full drug-vs-drug verdict index or provider rankings.